CDER director Janet Woodcock tells FDLI she’s amazed by industry’s enthusiastic response to her Center’s new breakthrough therapy designations program authorized by FDASIA legislation.
Legal experts review a series of court rulings that offer greater latitude for constructing First Amendment defense against allegations of unlawful off-label promotions.
FDA says it is partnering with a number of organizations to test an agency-developed handheld device that may detect counterfeit and substandard anti-malarial drugs.
Acting associate commissioner for regulatory affairs Melinda Plaisir says FDA is rapidly moving to more reliance of foreign regulatory partners with, so far, 17 joint inspections ─ “an unprecedented step.”
Confronting private sector law and public policy arguments, CDRH associate director for international affairs Kimberly Trautman describes efforts to develop a single audit program for medical devices, acceptable across multiple jurisdictions.
Keynoting the Food & Drug Law Institute’s 2013 annual conference, FDA commissioner Margaret Hamburg says she’s “enormously troubled” by the fact that “the agency’s responsibilities outstrip its resources” as a result of long-standing budgetary constraints.
Federal Register Notice: FDA releases a draft guidance, Safety Considerations for Container Labels and Carton Labeling Design to Minimize Medication Errors.